SNYNF - Regeneron/ Sanofi win label expansion for Dupixent in esophageal disorder
2024-01-25 14:56:31 ET
More on Regeneron Pharmaceuticals
- Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript)
- Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade)
- Regeneron Pharmaceuticals Inc. (REGN) American Society of Hematology 2023 Investor Conference - (Transcript)
- Regeneron’s high-dose Eylea, argenx’s Vyvgart injectable among latest approvals in Japan
- RBC ups Regeneron to outperform; cites Eylea patent win, Dupi sales